semaglutide gastroparesis Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient Managing Gastroparesis and SIBO associated

For chronic weight management, the FDA has approved specific formulationsWegovy (semaglutide 2.4 mg), Saxenda (liraglutide 3.0 mg), and Zepbound (tirzepatide)for adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it

The drug effectively dupes the brain into thinking weve had enough to eat, reducing our appetite and stopping us from consuming even more calories

This bidirectional relationship is vital for preventing and managing conditions such as irritable bowel syndrome, highlighting the importance of peptides in gut health